Markets showed divergent reactions to policy shifts on both sides of the Atlantic, with the Nasdaq hitting records while bond yields climbed.
US equity markets delivered a split performance, with the Nasdaq 100 climbing 0.35% to a fresh record close while the S&P 500 and Dow Jones struggled under pressure from pharmaceutical giant Eli Lilly. The weight-loss specialist plunged 14.1% after disappointing clinical trial data for its oral obesity treatment, despite raising full-year forecasts.
Apple provided crucial support to the Nasdaq with a 3.2% gain, benefiting from Trump's new semiconductor tariffs that notably excluded major US-based technology firms. This selective approach to trade policy highlighted the complex political calculations now influencing market movements across the technology sector.
However, the broader market showed signs of fatigue after recent earnings-driven rallies, with NYSE decliners outnumbering advancers. Fortinet exemplified the challenges facing some technology names, tumbling 22% on weak forward guidance, while Intel dropped 3.1% amid reports that Trump demanded the CEO's resignation over China ties.
Weekly jobless claims rose to 226,000, marking a one-month high and slightly exceeding expectations. While the labour market remains relatively resilient, the uptick provides another data point for Federal Reserve (Fed) officials to consider as they calibrate monetary policy.
The FTSE 100 managed only a modest 0.2% gain despite the Bank of England (BoE) delivering a quarter-point rate cut, with the benchmark finding support from pound weakness rather than domestic optimism. Sterling slipped 0.1% against the US dollar, though it maintained its position above the $1.34 level.
The more significant market reaction came in government bond markets, where gilts extended yesterday's selloff with yields rising particularly sharply across longer-dated maturities. This reflects the market's interpretation of the BoE's surprisingly cautious tone despite the rate reduction.
The central bank's 5-4 vote split revealed substantial resistance to further aggressive easing, with Monetary Policy Committee members expressing heightened concerns about persistent inflation pressures, particularly in food prices. Markets subsequently reduced expectations for future rate cuts, creating a stark contrast with Fed policy expectations.
President Trump's nomination of Stephen Miran to the Fed board, alongside speculation about Christopher Waller as a potential Fed chair replacement, signals continued pressure for more accommodative monetary policy. Both appointments would likely support further rate cuts, creating additional dollar weakness pressures.
This dovish shift at the Fed contrasts markedly with the BoE's more cautious approach, potentially supporting further pound strength despite today's modest decline.
Trump's escalating tariff policies, now pushing import duties to historic highs, add another layer of complexity to market dynamics. The selective application of these measures creates winners and losers across sectors, requiring careful stock selection in current conditions.
Corporate earnings delivered mixed results, with GlaxoSmithKline (GSK) gaining ground following a $370 million settlement payment from CureVac, while TBC Bank fell 11% despite apparently solid results.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.